× Try our new beta.tvnews.vanderbilt.edu website, for new pricing, more content, and immediate delivery of loans.
Search the Archive

Commercial: NASCAR / Warfarin / Xarelto Alto #1209112

CBS Evening News for Thursday, Feb 01, 2018
View other clips in this broadcast →

Material supplied by VTNA may be used for educational analysis or research only. Any editing, reproduction, publication, rebroadcast, public showing or public display may be prohibited by copyright laws.

He's a NASCAR champion who's faced thousands of drivers. She's a world class swimmer who stared down the best in her sport. But for both of them, the most challenging opponent was pee blood clots in my lung. It was really scary to my leg. I had to learn all I could to help protect myself. My doctor and I chose Xarelto outfits around town to help keep me protected. Xarelto Alto is the latest generation blood thinner that's proven to treat and reduce the risk of TVT and PD blood clots from happeni...
Duration:
00:01:32

Note to sponsor members: The Vanderbilt Television News Archive video player requires a modern operating system and browser to work properly. If you are experiencing playback problems, check the minimum requirements and adjust your setup accordingly. After adjustments, if you continue to experience problems, please contact us.

Welcome! Above is the abstract of the item that you're interested in viewing from the Vanderbilt Television News Archive's collection. You have three options if you'd like to view this item:

  • You may request a loan of this video by registering on our website and placing an order.
  • You may visit the Television News Archive on the Vanderbilt campus to view on-site from the Archive's collection.
  • If you are associated with a college or university, you may ask your library if they would like to become a sponsor, which would give students and faculty at your institution the ability to view items from our collection.

If you believe that you are associated with a sponsoring college or university and have received this message in error, please let us know.